A study of an inhaled anti-inflammatory medication for patients with COPD on Triple Therapy.

Are you struggling with COPD?


The Study

  • A 52-week study to assess the safety of an add-on inhaled medication for subjects with COPD.

Study Benefits

  • This medication is designed to reduce inflammation in COPD patients not adequately controlled on triple therapy
  • Free study related care and medication
  • Reduce the number of COPD breathing attacks

Study Volunteers Must Meet the Following Criteria

  • 40 years and older
  • Must have COPD diagnosis and being treated with triple therapy (ICS, LABA, LAMA)
  • Documented history of at least 1 moderate to severe breathing attack in the last year due to COVID

Study Participant Expectations

  • 56 week total study during
  • 8 clinic visits
  • 2 phone call visits


  • There is no cost to participate.
  • Patients who qualify may be compensated for time and travel